Skip to main content
Premium Trial:

Request an Annual Quote

Xcelience, UTEK, Pediatric Bioscience, University of California Davis MIND Institute, Colorado Bioscience Association, Biocrossroads, Connect

Premium
Xcelience Taps UTEK to ID, Transfer Pharma Services Technology
 
Contract pharmaceutical services firm Xcelience last week said that it has signed a technology-transfer agreement with UTEK.
 
Under the terms of the deal, UTEK will seek out new technologies and technology transfer opportunities worldwide to provide new products and services to Xcelience.
 
Xcelience, based in Tampa, Fla., specializes in preformulation, formulation development, analytical studies, and contract manufacturing.
 
UTEK is a specialty finance company that focuses on transferring new technologies from universities to businesses.
 

 
Pediatric Bioscience Sponsors Autism Discovery Research at UC’s MIND Institute
 
Pediatric Bioscience last week said that it has signed a collaborative research program discovery grant with the University of California Davis MIND Institute.
 
Under the terms of the agreement, Pediatric will sponsor research in the laboratory of Frank Sharp, professor of neurology in the school of medicine.
 
Pediatric will provide undisclosed funds to support a two-year effort in Sharp’s lab, and the state of California will provide matching funds.
 
Pediatric was formed in 2006 with the goal of bringing to market drugs and diagnostics for autism.
 

 
Colorado Governor Signs SBIR Matching Grants Biosciences Bill into Law
 
Colorado Governor Bill Ritter last week signed into law legislation that will provide $2.5 million in Small Business Innovative Resources matching grants to Colorado bioscience companies.
 
The bill, HB 1060, is an extension of last year’s HB 1360, which provided $2 million in bioscience research grants to Colorado universities and research institutions. The additional $500,000 in this year’s bill will match the federal grants available to small businesses at a rate of 50 cents for every federal dollar, up to a maximum of $50,000 per business.
 
The legislation “gives Colorado another avenue to strategically assist bioscience companies in the state,” Denise Brown, executive director of Colorado Bioscience Association, said in a statement. “Colorado’s strategy of growing our own takes a big step forward with the passage of HB 1060 and gives our bioscience companies a boost in commercializing their research.”
 

 
Indiana, San Diego Life Science Initiatives Co-Sponsor Biopharma Conference
 
Biocrossroads, Indiana’s initiative to develop life sciences companies, and Connect, San Diego’s life sciences-development initiative, said last week that they will co-sponsor a biopharmaceutical conference at the Salk Institute for Biological Studies in La Jolla, Calif., on Wed., May 30.
 
The summit is designed to discuss how to bring drugs to market more quickly and cost-effectively, and how to share risk through regional collaborations.
 
More information about the conference can be found here.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.